Second-Generation feedstock is the fastest-growing line in the global enzymes in biofuel market, expanding at 12.75% a year and slowly taking volume from the First-Generation grain and sugarcane processors that still hold 75.97% of 2025 revenue, worth USD 566 million.
The market as a whole was valued at USD 745 million in 2025. It is projected to reach USD 801 million in 2026 and USD 1461 million by 2034, a compound annual growth rate of 7.8% over the forecast period. Contrive Datum Insights presents these findings in its report, "Enzymes In Biofuel Market Size, Share & Industry Analysis, By Type (Amylases, Cellulases, Proteases, Lipases, Phytases), Application (Microorganisms, Plants, Animals), Biofuel type (Bioethanol, Biodiesel, Biogas), Feedstock generation (First-Generation, Second-Generation), Form (Liquid, Dry/Powder), and Regional Forecast, 2026-2034".
Buyers are bioethanol, biodiesel and biogas plants, plus the formulators and blenders that supply them. The enzymes are biological catalysts added during processing to break starch, cellulose, protein and fat into fermentable sugars or free fatty acids.
Why Second-Generation Outruns the Rest
The study names expanding renewable fuel blending mandates across major markets as the largest single contributor to growth, and rates the impact high. Cellulosic plants lean on enzymes that work on cellulose, so the type line closest to this shift moves fastest. Cellulases compounds at 10.65%, lifting its share of revenue from 30.07% to 37.99% and its value from USD 224 million to USD 555 million.
Other fast lines point the same way. Biogas grows at 10.53% within the biofuel type axis, while Bioethanol still leads it with 57.99% of 2025 revenue at USD 432 million. In form, Dry/Powder grows at 8.68%, though Liquid keeps the lead with 62.95%, or USD 469 million.
Two scenarios bracket the outcome. If cellulosic and biogas capacity is commissioned faster than announced and mandates in the United States, European Union, India and Indonesia are enforced in full, 2034 revenue reaches USD 1635 million. If financing and permitting delays push second-generation additions past 2034 and a major market exempts or delays its mandate step-ups, revenue stops at USD 1305 million.
Regions and the Slower Core
North America led in 2025 with 33.96% of global revenue, or USD 253 million, and reaches USD 438 million by 2034. Asia Pacific is gaining ground, moving from 28.05% of revenue in 2025 to 34.02% in 2034, with value climbing from USD 209 million to USD 497 million. The United States is the largest single country at USD 223 million, or 29.93% of global revenue. Middle East and Africa stays the smallest region throughout, at 4.97% of 2025 revenue and 5% by 2034.
The counterweight sits in the biggest line by type. Amylases carries 33.96% of 2025 revenue, worth USD 253 million, and remains the largest type through 2034 at 29.02%. Its growth of 5.86% trails the market's 7.8% by a visible margin, so the share it holds today erodes even as its revenue rises. By application, Microorganisms leads with 68.05% of 2025 revenue at USD 507 million.
The report covers five segmentation axes, with revenue and a growth rate for every line in every year from 2020 to 2034, along with bear, base and bull scenarios for the headline total. It addresses all five regions with country-level breakdowns, the competitive landscape and the research methodology behind each estimate. It is delivered as a PDF, and a free sample is available on request.